Focused on Finding Better Therapies for Patients with RAS Pathway-Driven Tumors
No patient with cancer should ever run out of options. From our lead investigational program in low-grade serous ovarian cancer (LGSOC) to KRAS mutant non-small lung cancer (NSCLC) to frontline metastatic cancer to other RAS-Pathway driven cancers, our goal is to make progress as quickly as possible to find solutions to cancers with high unmet need.
RAS-Pathway driven cancers comprise almost 30% of all human cancers and are driven by mutations in the RAS family of genes that includes KRAS, NRAS, and HRAS. Patients with a RAS pathway mutation tend to experience worse outcomes and a more significant impact on their lives than those without RAS pathway mutations. There has been only modest progress and a limited number of approved therapies. Novel therapies and combinations are urgently needed to deliver on the promise of better outcomes for patients. Find out more about our clinical trials.
At Verastem Oncology, we recognize and prioritize the importance of partnership with the research and patient advocacy communities to create and support approaches to better care. We are honored to support their work and collaborate on new initiatives where the opportunity to do better for patients exists.
Let’s Talk About LGSOC
This educational initiative, developed by Verastem and guided by advocates and patients, is aimed at bringing awareness and information to patients with LGSOC.
No One Missed
Verastem is proud to support Lungevity’s groundbreaking campaign to drive awareness of comprehensive biomarker testing in non-small cell lung cancer (NSCLC).
Therapeutic Accelerator Award
PanCan selected Verastem as the first recipient of its Therapeutic Accelerator Award, designed to accelerate research and support early-stage (Phase 1 and 2) clinical trials for new pancreatic cancer therapies.
Supporting patient groups who are leading the way in advancing awareness and care and support for patients is a priority for Verastem.